ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

Maintenance treatment with vedolizumab (Entyvio) appeared to be safe and effective in children with inflammatory bowel ...

The active ingredient in Entyvio is vedolizumab. Entyvio is a biologic drug that belongs to a group of drugs called integrin receptor antagonists. (A biologic drug is made from living organisms ...

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...